These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 38596266)

  • 41. Systematic review and meta-analysis of clinical outcomes comparison between different initial dialysis modalities in end-stage renal disease patients due to lupus nephritis prior to renal transplantation.
    Swai J; Zhao X; Noube JR; Ming G
    BMC Nephrol; 2020 May; 21(1):156. PubMed ID: 32357924
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognostic significance of pre-end-stage renal disease serum alkaline phosphatase for post-end-stage renal disease mortality in late-stage chronic kidney disease patients transitioning to dialysis.
    Sumida K; Molnar MZ; Potukuchi PK; Thomas F; Lu JL; Obi Y; Rhee CM; Streja E; Yamagata K; Kalantar-Zadeh K; Kovesdy CP
    Nephrol Dial Transplant; 2018 Feb; 33(2):264-273. PubMed ID: 28064159
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Current status of renoprotective procedures in the surgery of impaired kidneys].
    Dreikorn K; Horsch R
    Urologe A; 1984 Jan; 23(1):3-8. PubMed ID: 6539013
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events and residual renal function in dialysis patients: a meta-analysis of randomised controlled trials.
    Liu Y; Ma X; Zheng J; Jia J; Yan T
    BMC Nephrol; 2017 Jun; 18(1):206. PubMed ID: 28666408
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Kidney Disease in Type 2 Diabetes Mellitus and Benefits of Sodium-Glucose Cotransporter 2 Inhibitors: A Consensus Statement.
    Roy A; Maiti A; Sinha A; Baidya A; Basu AK; Sarkar D; Sanyal D; Biswas D; Maisnam I; Pandit K; Raychaudhuri M; Sengupta N; Chakraborty PP; Mukhopadhyay P; Raychaudhuri P; Sahana PK; Chatterjee P; Bhattacharjee R; Dasgupta R; Saraogi RK; Pal SK; Mukhopadhyay S; Mukhopadhyay S; Goswami S; Chowdhury S; Ghosh S;
    Diabetes Ther; 2020 Dec; 11(12):2791-2827. PubMed ID: 33025397
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mineral and bone disorders, morbidity and mortality in end-stage renal failure patients on chronic dialysis.
    Moldovan D; Rusu C; Kacso IM; Potra A; Patiu IM; Gherman-Caprioara M
    Clujul Med; 2016; 89(1):94-103. PubMed ID: 27004031
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Renal failure in the ICU: comparison of the impact of acute renal failure and end-stage renal disease on ICU outcomes.
    Clermont G; Acker CG; Angus DC; Sirio CA; Pinsky MR; Johnson JP
    Kidney Int; 2002 Sep; 62(3):986-96. PubMed ID: 12164882
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Strategies for preserving residual renal function in peritoneal dialysis patients.
    Nongnuch A; Assanatham M; Panorchan K; Davenport A
    Clin Kidney J; 2015 Apr; 8(2):202-11. PubMed ID: 25815178
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Perioperative Renoprotection: General Mechanisms and Treatment Approaches.
    Molinari L; Sakhuja A; Kellum JA
    Anesth Analg; 2020 Dec; 131(6):1679-1692. PubMed ID: 33186157
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment strategies to prevent renal damage in hypertensive children.
    Czarniak P; Zurowska A
    Curr Hypertens Rep; 2014 Apr; 16(4):423. PubMed ID: 24522942
    [TBL] [Abstract][Full Text] [Related]  

  • 51. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.
    Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Perkovic V; Hegbrant J; Strippoli GF
    Cochrane Database Syst Rev; 2014 May; (5):CD007784. PubMed ID: 24880031
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of Obesity on Modality Longevity, Residual Kidney Function, Peritonitis, and Survival Among Incident Peritoneal Dialysis Patients.
    Obi Y; Streja E; Mehrotra R; Rivara MB; Rhee CM; Soohoo M; Gillen DL; Lau WL; Kovesdy CP; Kalantar-Zadeh K
    Am J Kidney Dis; 2018 Jun; 71(6):802-813. PubMed ID: 29223620
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of Cardiovascular Events on End-Stage Renal Disease and Mortality in Patients With Chronic Kidney Disease Before Dialysis.
    Kuwahara M; Takehara E; Sasaki Y; Azetsu H; Kusaka K; Shikuma S; Akita W
    Ther Apher Dial; 2016 Feb; 20(1):12-9. PubMed ID: 26679409
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Rationale and study design of a randomized controlled trial to investigate the renoprotective effect of canagliflozin assessed by test of renal hemodynamics in diabetic kidney disease (the FAGOTTO study).
    Kato S; Kuwatsuka Y; Ando M; Tatematsu Y; Nishibori N; Maruyama S
    BMC Nephrol; 2023 Aug; 24(1):228. PubMed ID: 37537531
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of Chronic Kidney Disease on Risk for Vascular Events.
    Fan J; Salameh H
    Curr Vasc Pharmacol; 2016; 14(5):409-414. PubMed ID: 27456102
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pre-end-stage renal disease visit-to-visit systolic blood pressure variability and post-end-stage renal disease mortality in incident dialysis patients.
    Sumida K; Molnar MZ; Potukuchi PK; Thomas F; Lu JL; Yamagata K; Kalantar-Zadeh K; Kovesdy CP
    J Hypertens; 2017 Sep; 35(9):1816-1824. PubMed ID: 28399042
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Early referral to the nephrologist and timely initiation of renal replacement therapy: a paradigm shift in the management of patients with chronic renal failure.
    Obrador GT; Pereira BJ
    Am J Kidney Dis; 1998 Mar; 31(3):398-417. PubMed ID: 9506677
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
    de Zeeuw D; Remuzzi G; Parving HH; Keane WF; Zhang Z; Shahinfar S; Snapinn S; Cooper ME; Mitch WE; Brenner BM
    Kidney Int; 2004 Jun; 65(6):2309-20. PubMed ID: 15149345
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial.
    Ruggenenti P; Perna A; Loriga G; Ganeva M; Ene-Iordache B; Turturro M; Lesti M; Perticucci E; Chakarski IN; Leonardis D; Garini G; Sessa A; Basile C; Alpa M; Scanziani R; Sorba G; Zoccali C; Remuzzi G;
    Lancet; 2005 Mar 12-18; 365(9463):939-46. PubMed ID: 15766995
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term all-cause mortality and cardiovascular outcomes in Scottish children after initiation of renal replacement therapy: a national cohort study.
    Galiyeva DB; Jackson CA; Wild SH; Burns S; Hughes D; Traynor JP; Metcalfe W; Halbesma N
    Pediatr Nephrol; 2020 Apr; 35(4):677-685. PubMed ID: 31845058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.